Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 tulisokibart in moderately to severely active Crohn's disease
jRCT2031240196Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of tulisokibart in Crohn's disease (9 arms), sponsored by Merck & Co. Primary endpoints: Study 1: Clinical remission per CDAI at Week 52, Study 1: Endoscopic response at Week 52 and 2 more. Started Aug 2024; status: recruiting.
02
Drugs
tulisokibart
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on jRCT2031240196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240196.